Archean Chemical Industries Limited — Q3 FY26
Archean Chemical Industries reported a mixed Q3 FY26 with standalone revenue growing 12% YoY, but EBITDA declined 25% YoY to ₹69.9 crore, and PAT fell to ₹34.3 crore.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
Bromine derivatives capacity utilization to reach 50% by end of FY26
Current utilization is 30-35%; improvement expected as client approvals come through.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1